ArticleCureus2025
Neuronal Intermediate Filament-Positive Paraneoplastic Neurological Syndrome in Cervical Squamous Cell Carcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Neurological immune-related adverse events with anti-PD-1 based immunotherapy in cervical cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paraneoplastic neurological syndromes (PNS) are a group of neurological manifestations of a variety of carcinomas that result from the generation of paraneoplastic antibodies (PAb) against the tumors that subsequently attack the central nervous system (CNS). The resultant damage from these onconeural antibodies leads to significant neurological manifestations and syndromes, which are sometimes seen with certain antibodies and tumors; however, the presentation of PNS is diverse. Diagnosis is often delayed due to a lack of clinical suspicion. Unfortunately, late recognition leads to worse clinical outcomes as PNS requires prompt treatment to prevent permanent neurological damage. Cases that are diagnosed early and receive immediate treatment have significantly improved outcomes and restoration of neurological function. Non-responders to treatment likely have irreversible neuronal damage at the time the syndrome was recognized. Surgical resection of the tumor is paramount in the treatment paradigm because this would eliminate the source of PAb generation. Immunomodulatory therapy further reduces ongoing damage to the nervous system. We present an intriguing and the first documented case of PNS resulting from neuronal intermediate filament (NIF) antibodies detected in association with invasive cervical squamous cell carcinoma (SCC). The patient initially manifested with nonspecific weakness and loss of sensation that rapidly progressed to near complete loss of all motor function. Given the diverse presentation of PNS cases, heightened awareness and a high index of clinical suspicion are crucial for early diagnosis and prevention of further neurological compromise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.